Background {#Sec1}
==========

Clostridium difficile infection (CDI) is a leading cause of hospital -associated gastrointestinal illness which varies from of illness, which varies from asymptomatic infection, diarrhea, colitis, and pseudo-membranous colitis to death \[[@CR1]\]. *C. difficile* expresses two key virulence factors; the exotoxins, toxin A (TcdA) and toxin B (TcdB), which are glucosyltransferases targeting host-cell monomeric GTPases \[[@CR2]\]. In addition, some hypervirulent strains produce a third toxin, binary toxin or *C. difficile* transferase (CDT), which may contribute to the pathogenesis of CDI \[[@CR3]\]. The innate immune responses to *C. difficile* and its toxins are very important in the pathogenesis of CDI, although the adaptive immune responses have also been reported to influenze the severity of CDI \[[@CR4]\]. Diagnostic approaches are complex due to the availability of multiple testing strategies. Multistep algorithms using polymerase chain reaction (PCR) for the toxin gene(s) or single-step PCR on liquid stool samples have the best test performance characteristics \[[@CR5]\].

Risk factors for *C. difficile* infection (CDI) have typically been recent antibiotic exposure, advanced age, use of proton pump inhibitor, length of stay in healthcare settings, serious underlying illness, and immunocompromised conditions \[[@CR6], [@CR7]\]. Patients with CDI typically have extended lengths of stay in hospitals, and CDI is a frequent cause of large hospital outbreaks. The cost of treatment is expensive and the financial burden on the medical system is substantial \[[@CR6], [@CR8]\]. Earlier literature on this topic in Finland has been controversial. It has been suggested that the figures of health care associated CDI have decreased due to better infection control althought diagnostic methods have become more sensitive \[[@CR9]\]. In the other study the level of fluoroquinolone use has been associated to regional differences of CDI \[[@CR10]\]. We compare the incidence of CDI according to the National Infectious Diseases Register (NIDR, National Institute for Health and Welfare, Helsinki, Finland) in five university hospital districts in Finland. Moreover, we characterize CDI patients treated in the Oulu University Hospital (OUH) in one-year cohort.

Methods {#Sec2}
=======

The study was conducted in the Oulu University Hospital which is a tertiary care teaching hospital covering an area of approximately 407,000 inhabitants, with 985 beds and approx. 260,000 treatment days/year. The incidence of CD findings in five university hospital districts in Finland was compared using the data of the National Infectious Diseases Register (NIDR) of National Institute for Health and Welfare in the year 2013 \[[@CR11]\]. Noteworthy is that this register includes not just patients treated in the OUH but also patients treated in non-teaching hospitals, health centers and in private clinics in this district. Therefore the numbers of the cases treated in the OUH are clearly lower than cases in the whole OUH district.

The trend of *C. difficile* figures in the OUH the years 2010--2016 was analyzed according to the CD findings diagnosed in the microbiology laboratory of the OUH. The following data was collected from the hospital database: age, comorbidities, hospitalization history, antibiotic exposure, procedures, mortality data (30 d), CDI recurrences, and length of hospital stays. All cases underwent full medical-record review by an infectious diseases specialist (M. M-V.) to collect information on coexisting medical conditions, medication exposures, first laboratory-confirmed recurrences (i.e. positive specimen within 2 to 8 weeks after the last positive test). The term 'recurrent CDI' was used to denote either relapse or reinfection, as the diagnosis and management of both forms of recurrence are similar, and the two mechanisms are rarely differentiated in clinical practice.

The method for CDI detection was a polymerase chain reaction (PCR) -based, nucleic acid amplification test (NAAT) on CDI toxin B gene, *tcdB*, without preceding fecal culture. The samples were analyzed using GenomEra CDX™ test (Abacus Diagnostica, Turku, Finland). The incidences of *C. difficile* in (CD) gene typing CD pathogenicity (PaLoc) and CDT locus virulence factors were tested using in-house multiplex PCR method, using gel electrophoresis to test for *tcdA* and *tcdB* whether there is toxin production and whether the regulatory elements of the genes are mutated, like with deletions (e.g. ribotype 027). \[[@CR12]\] All samples with differing gene profiles were sent to the National Institute for Health and Welfare (THL, Turku, Finland) for further ribotyping.

Statistical analysis {#Sec3}
--------------------

Summary statistic are presented as mean and standard deviation (SD). The χ^2^ test and Fisher exact test was used to compare categorical variables, and the t-test and the Mann-Whitney U-test were used to compare continuous variables. *p* values \> 0.05 were considered as statistically significant. The statistical analyses were performed with IBM SPSS Statistics for Windows, version 22 (IBM Corp., Armonk, NY, USA).

Results {#Sec4}
=======

Five university hospitals used different methods for CDI diagnostics (Table [1](#Tab1){ref-type="table"}). In the study hospital (OUH) district the incidence of CD findings per 100,000 inhabitants (based on national register) was higher compared with other university hospital districts (159 vs. 70--84).Table 1Comparison of the incidence of Clostridium difficile cases per 100,000 inhabitants in five university hospital districts in Finland basing on the national register in the year 2013Hospital districtPopulation (million)Number of CD cases in national registerIncidence per 100,000 inhabitantsTest methodHospital A1.6117373F-Cldi culture and EIAHospital B0.536870F-CldiAg + F-Cldi cultureHospital C0.542084F-Cldi culture and GDHHospital D0.4638159F -CldTNhOHospital E0.216884NAAT for tcdB*F* faecal, *Cldi Clostridium difficile*, *EIA* enzyme immuno assay, *Ag* antigen, *GDH* glutamate dehydrogenase assay, *NAAT* nucleid acid amplification test, *tcdB* toxin B gene, *NhO* nucleid acid assay

In 2013, totally 6948 stool samples for CD toxin determination were examined in the OUH laboratory (Nordlab). From 1015 positive samples (14.5% of all), 261 different patients with 391 positive findings were treated in the study hospital. The main characteristics of the study population are shown in Table [2](#Tab2){ref-type="table"}. The mean age was 65 yrs. (range 16--102), while 37% were older than 75 yrs., 22% were diabetic and 29% immunocompromised (defined as a malignant disease or an immunosuppressive disease or treatment). Chronic inflammatory bowel disease was uncommon. Surprisingly, diarrhea as a symptom the day the stool sample was collected was mentioned in the patient documents in only 58% of cases (no data in 28/261 11% of cases).Table 2Main characteristics of adult CD patients (*N* = 261) treated in Oulu University Hospital in 2013VariableGender (M/F)125/136 (48/52%)Age (yrs, mean, SD)64.8 (19.1)Department^a^ (medicine/surgery)192/69 (74/26%)Positive CD culture32 (12%)Genotyping10 (3.8%)Diabetes58 (22%)Immunosuppressive76 (29%)IBD^b^7 (2.7%)Chronic renal disease18 (6.9%)Preceding antibiotics Cephalosporins127 (48%) Other beta-lactams102 (39%) Fluoroquinolones37 (14%) Clindamycin20 (7.7%) Vancomycin27 (10%) Antifungals10 (3.8%) Other antibiotics19 (7.3%) No data34 (13%)^a^The specialty where the patient was treated. In surgery gynaecology, otorhinolaryngology and ophthalmology are included. ^b^Chronic inflammatory bowel disease. *CD* Clostridium difficile

The treatment for the first episode of CDI was as follows: metronidazole in 167 cases (64%), per oral vancomycin in 42 (16%) and metronidazole and vancomycin combination therapy in 10 (3.9%). Fidaxomicin was given in four cases (1.6%). In 22 cases (8.4%) the only treatment was the cessation of the ongoing antibiotics and in 16 (6.1%) no data was found. In two situations, fecal transplantation was performed and in one case of toxic megacolon colectomy was performed. Recurrent infection was seen in 58 patients (22%). The number of recurrences was one in 34 patients, two in 14, three in six, four in two and five recurrences in two cases. There was no difference in the risk of recurrent infection between those treated with metronidazole or vancomycin (35/167, 27% vs. 13/42, 31% *p* = 0.17).

The all-cause 30 day mortality rate of the patients was 7.3% The majority of the cases (74%) were identified in the department of medicine, while the mortality rate was more than two times higher among surgical cases (13.0% vs. 5.2%, *p* = 0.03). The number of recurrences was significantly higher among survived CD patients (*p* = 0.003).

Ribotype analysis was performed in only 17 cases. Ribotype 178 was the most common, seven cases following 023 (four cases), 126 (two cases), and 014, 035, 045 and 143 (each one case). No ribotype 027 cases were identified.

As Table [3](#Tab3){ref-type="table"} shows, there was no increase either in the CD cases treated in the OUH in 2009--2016 or in the proportion of positive CD findings per all studied samples.Table 3Number of Clostridium difficile patients treated in the Oulu University Hospital in 2009--2016YearNumber of patients with positive samplesNumber of patients with negative samplesNumber of all patients with samples takenThe percentage of positive samples of all samples20092391103134217.820102211190141115.720112632376263910.020122311313154415.020132611547180814.420142871551183815.620152671507177415.120162301586181612.7Also the yearly number of all and negative faecal samples and proportion of positive samples are shown

Discussion {#Sec5}
==========

Our results show that the incidence of CD cases varied in five university hospital districts probably due the different diagnostic methods. Based on data from the OUH laboratory, the yearly numbers of CD cases treated in the OUH were quite constant during the years 2009--2016. In our one-year cohort, the number of recurrence was 22% and the 30 day all-cause mortality rate 7.3%. It is also noteworthy that the mortality among the patients treated in surgical wards was significantly higher than among the patients treated in medical wards. Because of the figures isallcause mortality we cannot exclude the contribution of the underlying diseases.

There may be several explanations why our hospital district had highest incidence of CD infections. We have used PCR-based diagnostics since the autumn 2010 whereas three other university hospitals used culture method when the survey was performed. In a population-based surveillance, the adoption of NAAT instead of toxin enzyme assay for diagnosis of CDI showed increase of 43--67% in CDI incidence \[[@CR12]\]. In a European review, the mean sensitivity of the PCR based methods was 86% and the mean specificity 97%, both much higher than with other methods \[[@CR13]\]. According to the current guidelines two or three steps algorithm should be use for diagnosing CDI instead of stand-alone test for toxin gene detection by NAAT or PCR \[[@CR14], [@CR15]\]. It is possible that some of the cases detected by NAAT or PCR represent colonization rather than true infection, given that NAAT detects the presence of the organism but not necessarily, if it is disease-causing \[[@CR16]\]. The rate of asymptomatic colonization in non-hospitalized adults is estimated to be 2% and up to 26%, in those with health care exposures \[[@CR17], [@CR18]\]. Asymptomatic colonization may explain some of our CD findings, because only 58% cases had diarrhea marked as a previous symptom, leaving a doubt that even almost 40% of the samples had no indication. Actually, this is against the current guidelines, which support to test only unformed stool samples \[[@CR14], [@CR15], [@CR19]\]. One-step procedure performed by a highly sensitive method demands appropriate sample collection. Unless adjustments based on methodology and population prevalence are considered, hospitals participating in public reporting of CDI rates will be at a disadvantage for performing the most sensitive testing methodologies \[[@CR1], [@CR16]\]. So, the methodological differences between regional laboratories hamper the comparisons between the hospital districts. One reason for differences in five university hospitals may also due to problems with the data collection from the hospital districts to the national CDI register.

Overall use of antibiotic agents is associated with a 3-fold increased risk of community-acquired CDI, but it has also been detected substantial variation in risk associated with different antimicrobial classes, with fluoroquinolones and clindamycin associated with the greatest enhancement of risk \[[@CR20]\]. In our study showed that most often cephalosporins (49%), other β-lactams (45%) and fluoroquinolones (14%) were used before CDI. In our material 7.7% were using clindamycin previously, even though it has been previously described as a high-risk antibiotic \[[@CR20]\]. That cephalosporins were used most often preceding CDI reflects our guidelines, where cefuroxime, a second-generation cephalosporin, is the first line antibiotic in several diagnoses, like community acquired pneumonia, pyelonephritis and community acquired bacteremia.

In our study mean recurrence rate was 22%. Recurrence rates for health care--associated CDI have been reported to vary from 5 to 50%, with an average of 20% \[[@CR21], [@CR22]\]. Also higher recurrence rates have been variously reported, from 3% to even 65% \[[@CR23], [@CR24]\]. There are three risk factors, which predict the risk for recurrent CDI: age \> 65 years, severe underlying disease and continued use of antibiotics for non-CDI infections \[[@CR25]\]. In our study mean age was 64.8 years, at least 61% had a significant comorbidity and 85% had a continued use of antibiotics for non-CDI infections.

Cochrane review in 2013 states on CDI treatment that current evidence leads to uncertainty whether mild CDI needs to be treated \[[@CR26]\]. The studies provide little evidence for antibiotic treatment of severe CDI as many studies excluded these patients. Improvement of the patient's clinical condition and prevention of spread of *C. difficile* infection to the other patients should be the two goals of therapy. Therefore an antibiotic that brings both symptomatic cure and bacteriologic cure \[[@CR25]\] is to be chosen. In our study, the treatment options mimicked the existing guidelines, 64% were treated with metronidazole, 16% with peroral vancomycin, metronidazole and vancomycin combination therapy was used in 3.9% of cases. Fidaxomicin was used only in four cases, but it has been reported that fidaxomicin provides improved sustained cure rates in patients with CDI compared with vancomycin \[[@CR27]\]. There were no statistical differences in treatment options between survivors and fatal cases in 30-day all case mortality. Two patients had fecal microbiota transplantation that year, since then its use has widened significantly in our university hospital district.

Our analyses have limitations. Collecting data retrospectively always has its limitations in the form of missing data. In addition, the case definition relied solely on positive results on *C. difficile* toxin or molecular assay because diarrhea is usually poorly documented in charts and existing guidelines for laboratory practice recommend *C. difficile* testing only on unformed stools. Laboratories should adopt stricter policies to reject formed stools when transitioning to NAAT.

Conclusions {#Sec6}
===========

Our PCR-based approach gave higher incidence of CD infections than other four university hospital districts in Finland. However, the number of the cases treated in the OUH remained quite stable and the main clinical characteristics of the cohort were in harmony with earlier literature. The quality of stool samples needs more critical evaluation in our hospital because almost 40% of the samples were formed stools, i.e. they actually did not represent diarrhea and might have therefore no indication for CD analysis.
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